BRANY (Biomedical Research Alliance of New York) has licensed its proprietary SMART (Study Management and Revenue Tracking) system to Tech Software, Inc., an information technology company that currently offers IRBManager, a fully Web-based software product that supports the administration of institutional review boards at hospitals throughout the country.
The BRANY SMART system is a clinical study management and revenue tracking system that allows study sites to develop study budgets and conduct cost analyses utilizing pricing information stored within the database. Users can also manage and store regulatory documents. The Web-based software-as-a-service (SaaS) also allows clients to track patient encounters, revenue, and accounts receivables. The SMART system, which is 21 CFR 11 ready, gives clinical research sites, research administration, and clinical trial offices the ability to develop their own customized work flows to track and monitor new study opportunities as they progress through a site or hospital’s internal review process. This includes budget, contract, conflict of interest, and IRB review. The SMART system also tracks enrollment against the study and includes integration with Tech’s IRBManager solution.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.